Any incident occurring during the transport of embryonic stem cells must be reported to the Director General of the Agence de la biomédecine by the holder of the import or export authorisation.
In the event of an incident likely to affect health safety, the Director General of the Agence de la biomédecine shall immediately inform the Director General of the Agence nationale de sécurité du médicament et des produits de santé and the Minister for Health.